Feature | HRS | May 15, 2019| Dave Fornell, Editor

Heart Rhythm Society 2019 Late-Breaking Clinical Trials

HRS late-breaker studies will highlight the biggest news in electrophysiology

HRS 2019 late breaking trials, late breaking presentations for the biggest news in electrophysiology (EP). #HRS #HRS2019 #HRS19

May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm Scientific Sessions. Here is a completed list of the studies presented with links to more information. This includes the latest in clinical research, techniques and technologies in cardiac electrophysiology (EP). For more details on HRS 2019, visit www.hrssessions.org.

 

Late Breaking Clinical Trials Session I
Thursday, May 9, 8 – 9:30 a.m.
   • Transcutaneous Electrical Vagus Nerve Stimulation To Suppress Atrial Fibrillation (TREAT AF): A Randomized Clinical Trial 

   • Prospective Randomized Comparison Of Rotor Ablation vs. Conventional Ablation For Treatment Of Persistent Atrial Fibrillation - The REAFFIRM Trial 

   • Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibillation (ERADICATE-AF) Trial  

   • Baroreflex Activation Therapy In Patients With Heart Failure With A Reduced Ejection Fraction  

   • His Corrective Pacing Or Bi-ventricular Pacing For Cardiac Resynchronization In Heart Failure: A Randomized Pilot Trial (HIS SYNC)

 

Late Breaking Clinical Trials Session II: New Data for Device Therapies
Friday, May 10, 1:30 – 3 p.m.
   • Update From The Prevention Of Arrhythmia Device Infection Trial (PADIT); Development Of The PADIT Infection Risk Score 

   • Decline In Ventricular Arrhythmia Events And Mortality In The Multicenter Automatic Defibrillator Implantation Trials  

   • After RAFT: Long Term Outcomes Of Cardiac Resynchronization Therapy  

   • Cardiac Resynchronization Therapy In Chemotherapy-induced Cardiomyopathy: Results Of The Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-induced Cardiomyopathy (MADIT-CHIC) Study

   • Understanding Outcomes With The S-ICD In Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Study: High Conversion Efficacy And Low Adverse Event Rate During The First 30 Days 

 

 
Late Breaking Clinical Trials Session III: Late-Breaking Science
Friday, May 10, 4:30 – 6 p.m.
   • Prospective Evaluation Of Feasibility, Electrophysiological And Echocardiographic Characteristics Of Left Bundle Branch Area Pacing 

   • Is Nonselective His Bundle Pacing Good Enough? Long-term Outcomes From The Geisinger-Rush HBP Registry

   • Preventive Ablation Of Ventricular Tachycardia In Patients With Myocardial Infarction: The BERLIN-VT Trial

   • Five-year Outcomes In Cardiac Surgery Patients With Atrial Fibrillation Undergoing Concomitant Surgical Ablation Versus No Ablation. The Long-term Follow-up of the Prague-12 Study  

   • Real-time Electrogram Analysis For Drivers Of Atrial Fibrillation (Radar): A Multi-center, FDA-IDE, Clinical Trial Of Persistent AF

   • Pulsed Field Ablation For Pulmonary Vein Isolation: Lesion Durability And Chronic Safety  

 

Late Breaking Clinical Trials Session IV: Innovations
Saturday, May 11, 10:30 a.m. - Noon 
   • First-in-human Chronic Implant Experience Of The Medtronic Substernal Extravascular Implantable Cardioverter Defibrillator

   • DIGITAL-AF II: Results From A Real-life Digital Atrial Fibrillation Screening Using Smartphones And Outcome Registry In The General Population

   • Non-invasive Localization Of Cardiac Arrhythmias Using Electromechanical Wave Ultrasound Imaging

   • A Novel Percutaneous Carotid Coil Filter For Stroke Prevention In Atrial Fibrillation: Outcomes Of The First-in-human CAPTURE Trial

   • Bipolar Catheter Ablation For The Treatment Of Refractory Scar-related Ventricular Tachycardia: A Multicenter, Prospective FDA IDE Study

 

 

Other HRS 2019 News:

Survey Shows Big Need for Patient Education on Their Implantable Electrophysiology Devices

Airport Security Body Scanners Do Not Interfere With Pacemakers, ICDs 

Studies Find Race and Gender Disparities in Implantable Heart Devices

HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy

 

New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias

VIDEO: Use of an Antibacterial Envelope to Reduce Infections for Pacemakers, ICDs — Interview with Khaldoun Tarakji, M.D.

VIDEO: Key Trends in Electrophysiology — Apple Watch to Detect AF and the CABANA Trial — Interview with Christine Albert, M.D.,

Find links to other Heart Rhythm Scientific Sessions news

 

 

Industry News at HRS 2019:

Philips and Medtronic Collaborate on Image-guided Atrial Fibrillation Treatment

Abbott Launches Next-generation Confirm RX Implantable Cardiac Monitor

FDA Approves Attain Stability Quad MRI SureScan Lead from Medtronic

Biosense Webster Launches Cartonet Analytics Software for Electrophysiology

 

Murj Launches Murj 2.0 Implantable Cardiac Device Management Software

Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System

Biocardia Receives FDA Clearance for Avance Steerable Introducer Family

 

Spacelabs Debuts Sentinel 11 Cardiology Information Management System

Stereotaxis Announces Next-generation Robotic Magnetic Navigation and Imaging Systems

Preventice Solutions Presents Real-World Performance Data on BodyGuardian Remote Monitoring System With AI

CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study

 

Related Content

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...
Overlay Init